Avista Healthcare
BRIDGEWATER, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the closing of its initial public offering of 7,647,500 ordinary shares at a public offering price of $7.00 per share. The number of shares issued at closing reflected the exercise in full of the underwriters’ option to […]
If approved, CAM2038 will provide patients and HCPs with flexible-dose weekly and monthly options for the treatment of opioid use disorder, with the goal of improving treatment adherence and reducing the burdens associated with daily medication. Plymouth Meeting, Pa. —July 16, 2018 —Braeburn announces that the U.S. Food and Drug Administration (FDA) has assigned a […]
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2018 in the medium-sized company category. “We are proud of every single person on the Optinose team […]
CORAL GABLES, Fla., June 25, 2018 /PRNewswire/ — Kramer Laboratories, Inc. (“Kramer”), a marketer of over-the-counter (OTC) foot care and specialty cough products, today announced the acquisition of Nizoral® (“Nizoral”), a leading anti-dandruff shampoo brand sold in North America and Latin America, from Janssen Pharmaceutica NV (a member of the Johnson & Johnson family of companies). Kramer is a portfolio company […]
YARDLEY, Pa., June 11, 2018 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 750,000 common shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional common shares. The offering consists of […]
NEW YORK and CORAL GABLES, Fla., May 2, 2018 /PRNewswire/ — Avista Capital Partners (“Avista”), a leading private equity firm, in partnership with Dana Holdings, a consumer healthcare-focused private investment group, today announced the completion of its acquisition of Kramer Laboratories, Inc. (“Kramer Laboratories,” “Kramer” or “the Company”), a marketer of over-the-counter (OTC) foot care and specialty cough products. Kramer, […]
WILMINGTON, Mass.–(BUSINESS WIRE)–Apr. 3, 2018– Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments. MPI is a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. Acquiring MPI will enhance Charles […]
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinosewas named the Emerging Company of the Year by Life Sciences Pennsylvania at its Annual Dinner last night. Additionally, at the ceremony and as previously announced, CEO Peter Miller was presented with the 2017 Frank […]
YARDLEY, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller has been chosen as the 2017 Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania. Additionally, Optinose has been honored as a finalist […]
Bridgewater, NJ – February 19, 2018 – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration (FDA) has approved OSMOLEX ER™, an amantadine extended release tablet, for the […]
NEW YORK, NY / LONDON, UK – February 8, 2018 – Funds advised by BC Partners (“BC Partners”), a leading international investment firm, today announced the signing of a definitive agreement whereby BC Partners will acquire Zest Dental Solutions (“Zest”) from Avista Capital Partners (“Avista”), a leading private equity firm in the healthcare sector. Financial […]
Princeton, N.J.— January 10, 2018 — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the Company has completed a $110 million mezzanine round of financing led by Wellington Capital Management. Other new investors participating in the financing include Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management, and Rock Springs Capital. Apple Tree Partners, the […]